– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was ...
MILAN -- An investigational 10-minute subcutaneous injection of ocrelizumab (Ocrevus) was non-inferior to the established IV infusion formulation of the drug in multiple sclerosis (MS), the phase III ...
Everyday Health on MSN
IVIg to SCIg: Considerations When Switching Immunoglobulin Therapies for Primary Immunodeficiency
Considering a switch from IVIg to SCIg for primary immunodeficiency? Explore differences in responsibility, side effects, ...
Dublin, Feb. 02, 2023 (GLOBE NEWSWIRE) -- The "Global Continuous Subcutaneous Insulin Infusion Market (2022-2027) by Products, Patient Type, End-Uses, and Geography, Competitive Analysis and the ...
MAHWAH, N.J., February 06, 2025--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, ...
Traditionally, isotope dilution kinetic studies of glucose, FFA, and amino acid metabolism in humans have primarily used intravenous infusion (and oral administration when tracing enteral absorption) ...
MAINZ, Germany, & MAHWAH, N.J.--(BUSINESS WIRE)--SCHOTT Pharma, a pioneer in pharma drug containment solutions and delivery systems, and KORU Medical Systems (NASDAQ: KRMD), a leading medical ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Continuous ...
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback